Skip to main content
. 2021 Feb 28;26(5):1307. doi: 10.3390/molecules26051307

Figure 7.

Figure 7

Luteolin protected MPP+-suppressed Erk1/2 and Drp1 in SH-SY5Y cells. Cells were pre-treated with 20 µM luteolin for 1 h, followed by treatment with 100 µM MPP+ for 24 h. (a) Expressions of Erk, p-Erk, Drp1 and p-Drp1 were analyzed by western blot analysis. Quantification of (b) p-Erk/Erk and (c) p-Drp1/Drp1 was shown in the bar graph. Cells were pre-treated with 20 µM luteolin and 10 µM roscovitine for 1 h, followed by treatment with 100 µM MPP+ for 24 h. (d) Expressions of Erk, p-Erk, Drp1 and p-Drp1 were analyzed by western blotting. Quantification of (e) p-Erk/Erk and (f) p-Drp1/Drp1 was shown in the bar graph. Data were normalized using β-actin as control. Results presented as the mean ± SD for triplicated independent experiments. Differences are statistically significant at * p < 0.05 versus the control group, and # p < 0.05 versus the MPP+ group.